TC
FATE icon

TwinBeech Capital’s Fate Therapeutics FATE Stock Holding History

TwinBeech Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-277,047
Closed -$2.8M – 708
2022
Q4 		$2.8M Buy
277,047
+63,879
+30% +$1.2M 0.05% 367
2022
Q3 		$4.78M Buy
+213,168
New +$6.16M 0.13% 200
2022
Q2 		– Sell
-53,897
Closed -$2.09M – 568
2022
Q1 		$2.09M Buy
+53,897
New +$2.09M 0.09% 240
2021
Q4 		– Sell
-34,427
Closed -$2.04M – 640
2021
Q3 		$2.04M Buy
34,427
+19,861
+136% +$1.56M 0.14% 217
2021
Q2 		$1.26M Buy
14,566
+7,066
+94% +$569K 0.15% 186
2021
Q1 		$618K Buy
+7,500
New +$719K 0.09% 267

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

TwinBeech Capital's FATE Position: Q1 2023 in Review

TwinBeech Capital sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 277,047 shares — an estimated $2.8M sold.

TwinBeech Capital first reported a position in FATE in Q1 2021 and held it in 6 quarters. The position peaked at $4.78M in Q3 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • TwinBeech Capital reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • TwinBeech Capital sold 277,047 Fate Therapeutics shares in Q1 2023, an estimated $2.8M.
  • TwinBeech Capital first reported a position in Fate Therapeutics in Q1 2021 and held it in 6 quarters.
  • TwinBeech Capital's Fate Therapeutics position peaked at $4.78M in Q3 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on TwinBeech Capital's 13F filing for Q1 2023, filed 15 May 2023.